Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been given a consensus rating of “Hold” by the five research firms that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $6.3333.

Several research firms have recently weighed in on ATOS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, October 8th. Zacks Research cut shares of Atossa Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Finally, Ascendiant Capital Markets lifted their price objective on shares of Atossa Genetics from $7.75 to $8.00 and gave the company a “buy” rating in a research note on Monday, December 8th.

Atossa Genetics Price Performance

Shares of ATOS opened at $0.63 on Monday. Atossa Genetics has a 1 year low of $0.55 and a 1 year high of $1.29. The stock’s fifty day moving average price is $0.77 and its two-hundred day moving average price is $0.83. The firm has a market cap of $81.45 million, a PE ratio of -2.63 and a beta of 1.09.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). Sell-side analysts anticipate that Atossa Genetics will post -0.22 earnings per share for the current fiscal year.

Institutional Trading of Atossa Genetics

A number of hedge funds and other institutional investors have recently made changes to their positions in ATOS. Hudson Bay Capital Management LP purchased a new stake in Atossa Genetics during the 2nd quarter worth about $26,000. Gallagher Capital Advisors LLC bought a new stake in shares of Atossa Genetics during the third quarter valued at about $27,000. JPMorgan Chase & Co. lifted its holdings in shares of Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after buying an additional 35,474 shares in the last quarter. Catalyst Funds Management Pty Ltd bought a new position in shares of Atossa Genetics in the second quarter valued at approximately $49,000. Finally, Bank of America Corp DE boosted its position in shares of Atossa Genetics by 55.7% in the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after acquiring an additional 35,629 shares during the period. 12.74% of the stock is currently owned by institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.